These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19093873)

  • 1. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer.
    Byrne JC; Downes MR; O'Donoghue N; O'Keane C; O'Neill A; Fan Y; Fitzpatrick JM; Dunn M; Watson RW
    J Proteome Res; 2009 Feb; 8(2):942-57. PubMed ID: 19093873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach.
    Qingyi Z; Lin Y; Junhong W; Jian S; Weizhou H; Long M; Zeyu S; Xiaojian G
    Cancer Invest; 2009 Aug; 27(7):794-801. PubMed ID: 19637042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells.
    Bindukumar B; Schwartz S; Aalinkeel R; Mahajan S; Lieberman A; Chadha K
    Prostate; 2008 Oct; 68(14):1531-45. PubMed ID: 18646040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
    Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
    J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression.
    Muramaki M; Miyake H; Yamada Y; Hara I
    Oncol Rep; 2006 Jan; 15(1):253-7. PubMed ID: 16328065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer.
    Fan Y; Murphy TB; Byrne JC; Brennan L; Fitzpatrick JM; Watson RW
    J Proteome Res; 2011 Mar; 10(3):1361-73. PubMed ID: 21166384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary markers for prostate cancer.
    Downes MR; Byrne JC; Pennington SR; Dunn MJ; Fitzpatrick JM; Watson RW
    BJU Int; 2007 Feb; 99(2):263-8. PubMed ID: 17092277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
    Sardana G; Jung K; Stephan C; Diamandis EP
    J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker.
    Skvortsov S; Schäfer G; Stasyk T; Fuchsberger C; Bonn GK; Bartsch G; Klocker H; Huber LA
    J Proteome Res; 2011 Jan; 10(1):259-68. PubMed ID: 20977276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
    Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
    Schostak M; Schwall GP; Poznanović S; Groebe K; Müller M; Messinger D; Miller K; Krause H; Pelzer A; Horninger W; Klocker H; Hennenlotter J; Feyerabend S; Stenzl A; Schrattenholz A
    J Urol; 2009 Jan; 181(1):343-53. PubMed ID: 19012935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer.
    Lexander H; Palmberg C; Hellman U; Auer G; Hellström M; Franzén B; Jörnvall H; Egevad L
    Proteomics; 2006 Aug; 6(15):4370-80. PubMed ID: 16888723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum proteomic study of prostate cancer with bone metastasis].
    Zhang XM; Shen Y; Xianyu ZQ
    Zhonghua Nan Ke Xue; 2010 Aug; 16(8):721-5. PubMed ID: 21090348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
    Kehinde EO; Maghrebi MA; Anim JT
    Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
    Bradford TJ; Wang X; Chinnaiyan AM
    Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.